Hints and tips:
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Diabetes medications still make up about 17 per cent of Lilly’s $22bn revenues, but in recent years it has lost ground to rivals such as Merck and Sanofi-Aventis....
...in animal health with Sanofi-Aventis and represent Merck with key external organisations....
...Merck said that Mr Clark would focus on strategy and would “oversee the planned formation of Merck’s joint venture in animal health with Sanofi-Aventis” in his role as chairman....
...The action comes as other large groups expand into a franchise long dominated by the insulin suppliers Novo Nordisk, Sanofi-Aventis and Eli Lilly....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it inched closer to making a hostile offer for the US biotech company....
...High factory automation has helped contain V-Zug’s costs, including a smart new computerised logistics centre opened this year. “Productivity is a key success factor for us,” Mr Buhofer says....
...Sanofi-Aventis’ US shares fell 4.2 per cent to close at $29.35....
...Sanofi-Aventis of France and Merck of the US on Tuesday agreed to combine their animal health operations, creating a joint venture with almost $5.3bn in annual sales and a 29 per cent share of the market...
...Sanofi-Aventis of France on Tuesday paid $1bn to Merck of the US as part of a deal to establish a joint venture which will be the world’s largest animal health business, with more than $5bn in annual sales...
...In pharmaceuticals, the government engineered the merger between Sanofi and Aventis to create a new champion rather than allow the Swiss Novartis to swallow it up....
...Merck, the US pharmaceutical group, has given the strongest indication yet of its intention to recreate an enlarged joint venture with Sanofi-Aventis of France to sell medicinal products for animals....
...Sanofi-Aventis, the French pharmaceutical group, is to buy out joint venture partner Merck’s stake in Merial, the animal health business, for $4bn to take full control of the company....
...A study by a British medical journal reported that a blood-thinning pill developed by the company worked better than Plavix, a rival drug made by Sanofi-Aventis....
...The World Health Organisation on Monday said that leading vaccine producers including Novartis, GlaxoSmithKline and Sanofi-Aventis had requested “wild type virus” samples of the A (H1N1) virus....
...Fred Hassan, a chemical engineer who ran Schering- Plough of the US, will also cease to be a chief executive once Merck of the US – run by Richard Clark, who trained in liberal arts and business – completes...
...Bankers on Tuesday indicated that Merck might have to offer first refusal rights of Schering-Plough’s animal health products to Merial, Merck’s joint venture with Sanofi-Aventis of France....
...Bristol-Myers Squibb could be next, with interest from both AstraZeneca of the UK and Sanofi-Aventis of France – both of which are partners with the US company in drug development....
...Then again, now that the Dutch group has flagged its interest in a takeover, Sanofi-Aventis and its rivals may come back with counter offers....
...Both GlaxoSmithKline and Sanofi-Aventis have also extended their generics activities, although so far concentrating on the development of cheaper versions of chemically-based medicines....
...Bernstein saw Bristol-Myers Squibb, GlaxoSmithKline and Sanofi Aventis among potential buyers of the franchise....
...His appointment comes as GlaxoSmithKline also seeks a new US head of operations, following the recent departure of Chris Viehbacher, who takes over as chief executive of Sanofi-Aventis of France at the start...
...Swiss drugmaker Novartis gained 23.7 per cent to SFr59.50 while in France, Sanofi-Aventis climbed 17.2 per cent to €44.44. Germany’s BMW was boosted by an upgrade from Goldman Sachs....
International Edition